180 related articles for article (PubMed ID: 10644071)
1. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity.
Olivier JC; Fenart L; Chauvet R; Pariat C; Cecchelli R; Couet W
Pharm Res; 1999 Dec; 16(12):1836-42. PubMed ID: 10644071
[TBL] [Abstract][Full Text] [Related]
2. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
Kreuter J; Ramge P; Petrov V; Hamm S; Gelperina SE; Engelhardt B; Alyautdin R; von Briesen H; Begley DJ
Pharm Res; 2003 Mar; 20(3):409-16. PubMed ID: 12669961
[TBL] [Abstract][Full Text] [Related]
3. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration.
Das D; Lin S
J Pharm Sci; 2005 Jun; 94(6):1343-53. PubMed ID: 15858853
[TBL] [Abstract][Full Text] [Related]
4. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
Alyautdin RN; Petrov VE; Langer K; Berthold A; Kharkevich DA; Kreuter J
Pharm Res; 1997 Mar; 14(3):325-8. PubMed ID: 9098875
[TBL] [Abstract][Full Text] [Related]
5. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells.
Ramge P; Unger RE; Oltrogge JB; Zenker D; Begley D; Kreuter J; Von Briesen H
Eur J Neurosci; 2000 Jun; 12(6):1931-40. PubMed ID: 10886334
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections.
Schröder U; Sabel BA
Brain Res; 1996 Feb; 710(1-2):121-4. PubMed ID: 8963650
[TBL] [Abstract][Full Text] [Related]
7. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro.
Alyaudtin RN; Reichel A; Löbenberg R; Ramge P; Kreuter J; Begley DJ
J Drug Target; 2001 Jun; 9(3):209-21. PubMed ID: 11697206
[TBL] [Abstract][Full Text] [Related]
8. [Transport of the hexapeptide dalargin across the hemato-encephalic barrier into the brain using polymer nanoparticles].
Aliautdin RN; Petrov VE; Ivanov AA; Kreuter J; Kharkevich DA
Eksp Klin Farmakol; 1996; 59(3):57-60. PubMed ID: 8974587
[TBL] [Abstract][Full Text] [Related]
9. Circadian phase-dependent antinociceptive reaction in mice determined by the hot-plate test and the tail-flick test after intravenous injection of dalargin-loaded nanoparticles.
Ramge P; Kreuter J; Lemmer B
Chronobiol Int; 1999 Nov; 16(6):767-77. PubMed ID: 10584177
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle technology for delivery of drugs across the blood-brain barrier.
Schroeder U; Sommerfeld P; Ulrich S; Sabel BA
J Pharm Sci; 1998 Nov; 87(11):1305-7. PubMed ID: 9811481
[TBL] [Abstract][Full Text] [Related]
11. Effects of apolipoproteins on dalargin transport across the blood-brain barrier.
Shamenkov DA; Petrov VE; Alyautdin RN
Bull Exp Biol Med; 2006 Dec; 142(6):703-6. PubMed ID: 17603675
[TBL] [Abstract][Full Text] [Related]
12. [Effect of diameter of adriamycin polybutylcyanoacrylate nanoparticles on liver targeting].
Shen LF; Wang X; Wang C; Zhao K; Liu XJ; Shen HJ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):732-6, 741. PubMed ID: 17062941
[TBL] [Abstract][Full Text] [Related]
13. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity.
Rempe R; Cramer S; Hüwel S; Galla HJ
Biochem Biophys Res Commun; 2011 Mar; 406(1):64-9. PubMed ID: 21295549
[TBL] [Abstract][Full Text] [Related]
14. Nanotoxicity of poly(n-butylcyano-acrylate) nanoparticles at the blood-brain barrier, in human whole blood and in vivo.
Kolter M; Ott M; Hauer C; Reimold I; Fricker G
J Control Release; 2015 Jan; 197():165-79. PubMed ID: 25445700
[TBL] [Abstract][Full Text] [Related]
15. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study.
Alyautdin RN; Tezikov EB; Ramge P; Kharkevich DA; Begley DJ; Kreuter J
J Microencapsul; 1998; 15(1):67-74. PubMed ID: 9463808
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats.
Ambruosi A; Khalansky AS; Yamamoto H; Gelperina SE; Begley DJ; Kreuter J
J Drug Target; 2006 Feb; 14(2):97-105. PubMed ID: 16608736
[TBL] [Abstract][Full Text] [Related]
17. Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice.
Schroeder U; Schroeder H; Sabel BA
Life Sci; 2000; 66(6):495-502. PubMed ID: 10794066
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model.
Wang CX; Huang LS; Hou LB; Jiang L; Yan ZT; Wang YL; Chen ZL
Brain Res; 2009 Mar; 1261():91-9. PubMed ID: 19401168
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice.
Zhang ZM; Yang XY; Deng SH; Xu W; Gao HQ
Chin Med J (Engl); 2007 Aug; 120(15):1336-42. PubMed ID: 17711740
[TBL] [Abstract][Full Text] [Related]
20. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles.
Tian XH; Lin XN; Wei F; Feng W; Huang ZC; Wang P; Ren L; Diao Y
Int J Nanomedicine; 2011; 6():445-52. PubMed ID: 21445277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
